# A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

> **NCT04205175** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Hospital Los Angeles** · enrollment: 20 (estimated)

## Conditions studied

- Hemophilia A With Inhibitor

## Interventions

- **DRUG:** Feiba

## Key facts

- **NCT ID:** NCT04205175
- **Lead sponsor:** Children's Hospital Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-01
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04205175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04205175, "A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04205175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*